Nuvalent Change in Accounts Payable 2021-2025 | NUVL

Nuvalent change in accounts payable for the twelve months ending March 31, 2025 was $0.022B, a 116.45% increase year-over-year.

  • Nuvalent annual change in accounts payable for 2024 was $-0.004B, a 286.68% decline from 2023.
  • Nuvalent annual change in accounts payable for 2023 was $0.002B, a 48.5% decline from 2022.
  • Nuvalent annual change in accounts payable for 2022 was $0.004B, a 156.67% increase from 2021.

Nuvalent Change in Accounts Payable 2021-2025 | NUVL

  • Nuvalent annual change in accounts payable for 2024 was $-0.004B, a 286.68% decline from 2023.
  • Nuvalent annual change in accounts payable for 2023 was $0.002B, a 48.5% decline from 2022.
  • Nuvalent annual change in accounts payable for 2022 was $0.004B, a 156.67% increase from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$222.7B
Amgen (AMGN)$161.5B
Gilead Sciences (GILD)$142.5B
Vertex Pharmaceuticals (VRTX)$123.1B
Bristol Myers Squibb (BMY)$98.7B
GSK (GSK)$81B
CSL (CSLLY)$78.2B
Regeneron Pharmaceuticals (REGN)$60.4B
Alnylam Pharmaceuticals (ALNY)$42.1B
Argenex SE (ARGX)$34.4B
BioNTech SE (BNTX)$27.4B
Royalty Pharma (RPRX)$20.3B
Biogen (BIIB)$19.8B
Insmed (INSM)$18.3B
Illumina (ILMN)$15.8B
Genmab (GNMSF)$14B
Genmab (GMAB)$14B
Incyte (INCY)$13.6B
Moderna (MRNA)$13.3B
Exelixis (EXEL)$12.3B
BioMarin Pharmaceutical (BMRN)$11.3B
QIAGEN (QGEN)$10.8B
Ascendis Pharma (ASND)$10.8B
Swedish Orphan Biovitrum (BIOVF)$10.4B
Exact Sciences (EXAS)$10.1B
Verona Pharma American Depositary Share (VRNA)$8.9B
Bio-Techne Corp (TECH)$8.5B
Blueprint Medicines (BPMC)$8.4B
Regencell Bioscience Holdings (RGC)$8.2B
Roivant Sciences (ROIV)$7.9B